Clinical trials: Movement Abnormalities
Tardive Dyskinesia
Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Phase 3, open-label, study to evaluate the safety and tolerability of NBI-98854 administered once daily (qd) for a total of 48 weeks of treatment.
- Trial name
- Kinect 4 (NCT02405091)
- Testing
- NBI-98854
- Where
- 48 sites in United States, Canada and 1 more
- Volunteers
- 167 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease, Parkinsons Disease With Dementia
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder causing motor and non-motor symptoms. PD is characterized by death of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta and…
- Trial name
- PD Nilotinib (NCT02954978)
- Testing
- Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Georgetown University
Parkinson Disease, Parkinsonian Disorders
Usefulness of α-synuclein as a Marker for Early Diagnosis of Parkinson's Disease in Skin Biopsy.
Parkinson's disease (PD) is a degenerative disease that can be difficult to diagnose. The clinicopathological studies had demonstrated a 76% accuracy in the clinical diagnosis of PD.
- Trial name
- NCT01380899
- Testing
- Biopsy of skin
- Where
- Mexico
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Cerebral Palsy
Development of a Robotic Ankle Assist Device
The overall objectives of this work is to establish feasibility of a robotic ankle assist device (RAAD) to improve mobility in free-living settings and to establish the RAAD as an effective tool to provide increased dose and…
- Trial name
- NCT04516343
- Testing
- Robotic Ankle Assist Device (RAAD)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- BiOMOTUM, Inc.
Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.
- Trial name
- NCT02669433
- Testing
- RVT-101 35 mg, RVT-101 70 mg
- Where
- 65 sites in United States, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Axovant Sciences Ltd.
Parkinson Disease, Sleep Disorder
Light Therapy for PD - Dose Selection
This study aims to determine the most effective dose of light therapy to improve sleep in people with Parkinson's Disease. Four groups of participants will receive bright-white or dim-red light therapy at different times…
- Conditions
- Parkinson Disease, Sleep Disorder, Fatigue
- Trial name
- NCT04291014
- Testing
- SunRay Light Boxes
- Where
- 25 sites in United States
- Volunteers
- 203 people
- Sponsor
- Massachusetts General Hospital
Essential Tremor
Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor
To determine the relationship between drug plasma levels and safety, tolerability and efficacy in patients with essential tremors after dosing with Sodium oxybate
- Trial name
- NCT00598078
- Testing
- Sodium Oxybate
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jazz Pharmaceuticals
Wilson's Disease
Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily).
A randomised, open-label study evaluating the pharmacokinetics, safety, and tolerability of a new once daily dose of 900mg of TETA 4HCL by comparing it against the current marketed Cuprior® formulation (450mg trientine base…
- Trial name
- NCT06128954
- Testing
- 900mg TETA 4HCl Once Daily Formulation, 900mg TETA 4HCl Cuprior®
- Where
- United Kingdom
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Orphalan
Parkinson's Disease, Depression
rTMS for Motor and Mood Symptoms of Parkinson's Disease
The purpose of this study is to determine if repetitive transcranial magnetic stimulation (rTMS), a method of noninvasive brain stimulation) is effective in the treatment of the motor (movement) and mood symptoms due to…
- Trial name
- MASTER-PD (NCT01080794)
- Testing
- Repetitive transcranial magnetic stimulation (rTMS)
- Where
- 6 sites in United States, Canada
- Volunteers
- 61 people
- Sponsor
- Beth Israel Deaconess Medical Center
Idiopathic Parkinson's Disease
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
This is a Phase 3, 52-week, open-label, flexible-dose, multinational, multicenter study to evaluate the safety and tolerability of istradefylline 20 or 40 mg/d in subjects with moderate to severe PD with motor fluctuations and…
- Trial name
- NCT02610231
- Testing
- Istradefylline 20 mg or 40 mg
- Where
- 55 sites in United States, Canada and 6 more
- Volunteers
- 239 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Wilson Disease
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
This study is being conducted to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of ALXN1840 versus standard of care in pediatric participants with Wilson disease (WD).
- Trial name
- NCT05047523
- Testing
- ALXN1840, Standard of Care
- Where
- 20 sites in Australia, France and 5 more
- Volunteers
- 40 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Sleep Disorder, Restless Legs Syndrome
Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder
The purpose of this research study is to see if the level of serum ferritin differs based on how often oral iron (in the form of ferrous sulfate) is given to children with restless leg syndrome/periodic limb movement disorder.
- Conditions
- Sleep Disorder, Restless Legs Syndrome, Periodic Limb Movement Sleep Disorder, Iron-deficiency
- Trial name
- NCT04610827
- Testing
- Ferrous sulfate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic
Huntingtons Disease
A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease
Study BP40410 is an open-label, adaptive multiple-dose clinical study designed to characterize the PK of RO7234292 (RG6042) in plasma and CSF as well as the acute time course and recovery profile of CSF mHTT lowering in response…
- Trial name
- NCT04000594
- Testing
- RO7234292 (RG6042)
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Parkinson Disease
Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa
The survey is conducted to collect safety and effectiveness information in Parkinson's Disease patients treated with Pramipexole without concomitant L-Dopa supplementation in the daily clinical settings in Japan.
- Trial name
- NCT00613301
- Where
- 119 sites in Japan
- Volunteers
- 416 people
- Sponsor
- Boehringer Ingelheim
Huntington Disease, Chorea
Risperidone for the Treatment of Huntington's Disease Involuntary Movements
The purpose of this study is to assess the safety and benefit of risperidone for the treatment of chorea (involuntary movements) in Huntington's disease.
- Trial name
- NCT04201834
- Testing
- Risperidone, BioStamp nPoint device
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Rochester
Parkinson's Disease, Tremor
Pilot Study for Automated Deep Brain Stimulation Programming
The clinical utility of deep brain stimulation (DBS) for the treatment of movement disorders such as Parkinson's disease has been well established; however, there is a great disparity in outcomes among DBS recipients due to…
- Conditions
- Parkinson's Disease, Tremor, Bradykinesia
- Trial name
- NCT02046863
- Testing
- Automated Programming
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Parkinson's Disease
Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease
Continuous deep brain stimulation (cDBS) is an established therapy for the major motor signs in Parkinson's disease. Currently, cDBS is limited to "open-loop" stimulation, without real-time adjustment to the patient's state of…
- Trial name
- aDBS (NCT02384421)
- Testing
- Adaptive DBS (Activa PC+S Neurostimulator), Continuous DBS (Activa PC+S Neurostimulator)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Huntington's Disease
Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease
In individuals with Huntington's disease (HD), chorea may contribute to balance problems and difficulties with walking, sit to stand transfers and stair climbing that in turn may contribute to high fall rates.
- Trial name
- NCT01451463
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University
Parkinson Disease
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)
The purpose of this study is to assess the effect of tavapadon on the change from baseline in total daily hours of "on" time without troublesome dyskinesia in L-Dopa-treated participants with Parkinson's Disease (PD) who are…
- Trial name
- NCT04542499
- Testing
- Tavapadon
- Where
- 146 sites in United States, Australia and 12 more
- Volunteers
- 507 people
- Sponsor
- AbbVie
Parkinson Disease
Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
The purpose of this project is to assess the change in dopamine transporter density in Parkinson's disease subjects during a sixty month period including a nine month treatment trial of levodopa.
- Trial name
- ELLDOPA (NCT00134784)
- Testing
- [123I]B-CIT SPECT imaging
- Volunteers
- 142 people
- Sponsor
- Institute for Neurodegenerative Disorders